References of "Nobili, F"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: an EADC study
Bosco, P.; Redolfi, A.; Bocchetta, M. et al

in Alzheimer's & Dementia : The Journal of the Alzheimer's Association (2017)

Detailed reference viewed: 31 (1 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of vasculare risk factors in different stages of prodromal Alzheimer’s disease and its influence on cognitive decline
Bos, I.; Vos, S.; Frölich, L. et al

in Alzheimer's & Dementia : The Journal of the Alzheimer's Association (2016), 12(7), 1059-1061

Detailed reference viewed: 30 (0 ULiège)
Full Text
Peer Reviewed
See detailThe use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
Bochetta, M; Galluzi, S; Kehoe, P.G. et al

in Alzheimer's & Dementia (2015), 11(2), 195-206

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive ... [more ▼]

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Abeta42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. [less ▲]

Detailed reference viewed: 23 (0 ULiège)
Full Text
Peer Reviewed
See detailPrevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage
Vos; VERHEY, F.; Frölich, L. et al

in Brain : A Journal of Neurology (2015), 138

Detailed reference viewed: 82 (6 ULiège)